Cong Z Zhao, MD

520 S. Eagle Road | 208-706-6300 | zhaoco@slhs.org

10/21/2019

Mrs. Tami Eide eidet@dhw.idaho.gov

Mrs. Eide,

As a neurologist taking care of patients with tardive dyskinesia and Huntington's disease, there has historically been lack of options for both populations. It has been refreshing to finally have options that I can tell patients that are FDA approved for the treatment of Huntington's chorea movements and dyskinesias.

Both population of patients are often disable and unable to be gainfully employed and they will not be able to afford this medication without government support. I am also sure that there are many patients that have not been diagnosed as well that would benefit from treatment. Continued coverage for this medication would be the only feasible option for the majority of my patients to get on medication. Please consider continued coverage in this state of Austedo (Deutetrabenazine) for tardive dyskinesia and Huntington's disease associated chorea.

Sincerely

Cong Zhi Zhao, MD

Movement Specialist